Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors

Charles Erlichman, Manuel Hidalgo, Joseph P. Boni, Patricia Martins, Susan E. Quinn, Charles Zacharchuk, Peter Amorusi, Alex A. Adjei, Eric K. Rowinsky

Research output: Contribution to journalArticle

Abstract

Purpose: The maximum tolerated dose (MTD) and the dose-limiting toxicities of EKB-569, a selective, irreversible inhibitor of the epidermal growth factor receptor (EGFR), when administered orally once daily on an intermittent-dose schedule (14 days of a 28-day cycle) or on a continuous-dose schedule (each day of a 28-day cycle), were determined in patients with advanced solid tumors. Patients and Methods: Planned dose escalation was 25, 50, 75, 125, 175, and 225 mg. Pharmacokinetic sampling was performed on days 1 and 14 for the intermittent-dose cohort and on days 1 and 15 for the continuous-dose cohort. Results: Thirty patients received a median of two cycles (range, one to 10 cycles) in the intermittent-dose cohort; 29 patients received a median of three cycles (range, one to eight cycles) in the continuous-dose cohort. Dose-limiting toxicity was grade 3 diarrhea, and the MTD was 75 mg EKB-569 per day for both cohorts. Other common toxicities included rash, nausea, and asthenia. Exposure to EKB-569 was dose proportional. At the MTD, the mean ± standard deviation terminal half-life was 21.7 ± 4.2 hours and peak concentration increased 1.2-fold from day 1 to day 14/15. No major antitumor responses were observed. However, one patient with non-small-cell lung cancer and one with cutaneous squamous cell carcinoma had stable disease for 33 and 24 weeks, respectively. Conclusion: The MTD of once-daily oral EKB-569 is 75 mg. The tolerable toxicity profile and long half-life of this irreversible EGFR inhibitor warrant its further evaluation as a single agent and in combination with other drugs.

Original languageEnglish (US)
Pages (from-to)2252-2260
Number of pages9
JournalJournal of Clinical Oncology
Volume24
Issue number15
DOIs
StatePublished - May 20 2006
Externally publishedYes

Fingerprint

Epidermal Growth Factor Receptor
Maximum Tolerated Dose
Neoplasms
Half-Life
Appointments and Schedules
Asthenia
Exanthema
Non-Small Cell Lung Carcinoma
Nausea
Squamous Cell Carcinoma
Diarrhea
Pharmacokinetics
EKB 569
Skin
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Erlichman, C., Hidalgo, M., Boni, J. P., Martins, P., Quinn, S. E., Zacharchuk, C., ... Rowinsky, E. K. (2006). Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. Journal of Clinical Oncology, 24(15), 2252-2260. https://doi.org/10.1200/JCO.2005.01.8960

Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. / Erlichman, Charles; Hidalgo, Manuel; Boni, Joseph P.; Martins, Patricia; Quinn, Susan E.; Zacharchuk, Charles; Amorusi, Peter; Adjei, Alex A.; Rowinsky, Eric K.

In: Journal of Clinical Oncology, Vol. 24, No. 15, 20.05.2006, p. 2252-2260.

Research output: Contribution to journalArticle

Erlichman, C, Hidalgo, M, Boni, JP, Martins, P, Quinn, SE, Zacharchuk, C, Amorusi, P, Adjei, AA & Rowinsky, EK 2006, 'Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors', Journal of Clinical Oncology, vol. 24, no. 15, pp. 2252-2260. https://doi.org/10.1200/JCO.2005.01.8960
Erlichman, Charles ; Hidalgo, Manuel ; Boni, Joseph P. ; Martins, Patricia ; Quinn, Susan E. ; Zacharchuk, Charles ; Amorusi, Peter ; Adjei, Alex A. ; Rowinsky, Eric K. / Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. In: Journal of Clinical Oncology. 2006 ; Vol. 24, No. 15. pp. 2252-2260.
@article{ef37014abb234c2882132c8666cfd4ac,
title = "Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors",
abstract = "Purpose: The maximum tolerated dose (MTD) and the dose-limiting toxicities of EKB-569, a selective, irreversible inhibitor of the epidermal growth factor receptor (EGFR), when administered orally once daily on an intermittent-dose schedule (14 days of a 28-day cycle) or on a continuous-dose schedule (each day of a 28-day cycle), were determined in patients with advanced solid tumors. Patients and Methods: Planned dose escalation was 25, 50, 75, 125, 175, and 225 mg. Pharmacokinetic sampling was performed on days 1 and 14 for the intermittent-dose cohort and on days 1 and 15 for the continuous-dose cohort. Results: Thirty patients received a median of two cycles (range, one to 10 cycles) in the intermittent-dose cohort; 29 patients received a median of three cycles (range, one to eight cycles) in the continuous-dose cohort. Dose-limiting toxicity was grade 3 diarrhea, and the MTD was 75 mg EKB-569 per day for both cohorts. Other common toxicities included rash, nausea, and asthenia. Exposure to EKB-569 was dose proportional. At the MTD, the mean ± standard deviation terminal half-life was 21.7 ± 4.2 hours and peak concentration increased 1.2-fold from day 1 to day 14/15. No major antitumor responses were observed. However, one patient with non-small-cell lung cancer and one with cutaneous squamous cell carcinoma had stable disease for 33 and 24 weeks, respectively. Conclusion: The MTD of once-daily oral EKB-569 is 75 mg. The tolerable toxicity profile and long half-life of this irreversible EGFR inhibitor warrant its further evaluation as a single agent and in combination with other drugs.",
author = "Charles Erlichman and Manuel Hidalgo and Boni, {Joseph P.} and Patricia Martins and Quinn, {Susan E.} and Charles Zacharchuk and Peter Amorusi and Adjei, {Alex A.} and Rowinsky, {Eric K.}",
year = "2006",
month = "5",
day = "20",
doi = "10.1200/JCO.2005.01.8960",
language = "English (US)",
volume = "24",
pages = "2252--2260",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "15",

}

TY - JOUR

T1 - Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors

AU - Erlichman, Charles

AU - Hidalgo, Manuel

AU - Boni, Joseph P.

AU - Martins, Patricia

AU - Quinn, Susan E.

AU - Zacharchuk, Charles

AU - Amorusi, Peter

AU - Adjei, Alex A.

AU - Rowinsky, Eric K.

PY - 2006/5/20

Y1 - 2006/5/20

N2 - Purpose: The maximum tolerated dose (MTD) and the dose-limiting toxicities of EKB-569, a selective, irreversible inhibitor of the epidermal growth factor receptor (EGFR), when administered orally once daily on an intermittent-dose schedule (14 days of a 28-day cycle) or on a continuous-dose schedule (each day of a 28-day cycle), were determined in patients with advanced solid tumors. Patients and Methods: Planned dose escalation was 25, 50, 75, 125, 175, and 225 mg. Pharmacokinetic sampling was performed on days 1 and 14 for the intermittent-dose cohort and on days 1 and 15 for the continuous-dose cohort. Results: Thirty patients received a median of two cycles (range, one to 10 cycles) in the intermittent-dose cohort; 29 patients received a median of three cycles (range, one to eight cycles) in the continuous-dose cohort. Dose-limiting toxicity was grade 3 diarrhea, and the MTD was 75 mg EKB-569 per day for both cohorts. Other common toxicities included rash, nausea, and asthenia. Exposure to EKB-569 was dose proportional. At the MTD, the mean ± standard deviation terminal half-life was 21.7 ± 4.2 hours and peak concentration increased 1.2-fold from day 1 to day 14/15. No major antitumor responses were observed. However, one patient with non-small-cell lung cancer and one with cutaneous squamous cell carcinoma had stable disease for 33 and 24 weeks, respectively. Conclusion: The MTD of once-daily oral EKB-569 is 75 mg. The tolerable toxicity profile and long half-life of this irreversible EGFR inhibitor warrant its further evaluation as a single agent and in combination with other drugs.

AB - Purpose: The maximum tolerated dose (MTD) and the dose-limiting toxicities of EKB-569, a selective, irreversible inhibitor of the epidermal growth factor receptor (EGFR), when administered orally once daily on an intermittent-dose schedule (14 days of a 28-day cycle) or on a continuous-dose schedule (each day of a 28-day cycle), were determined in patients with advanced solid tumors. Patients and Methods: Planned dose escalation was 25, 50, 75, 125, 175, and 225 mg. Pharmacokinetic sampling was performed on days 1 and 14 for the intermittent-dose cohort and on days 1 and 15 for the continuous-dose cohort. Results: Thirty patients received a median of two cycles (range, one to 10 cycles) in the intermittent-dose cohort; 29 patients received a median of three cycles (range, one to eight cycles) in the continuous-dose cohort. Dose-limiting toxicity was grade 3 diarrhea, and the MTD was 75 mg EKB-569 per day for both cohorts. Other common toxicities included rash, nausea, and asthenia. Exposure to EKB-569 was dose proportional. At the MTD, the mean ± standard deviation terminal half-life was 21.7 ± 4.2 hours and peak concentration increased 1.2-fold from day 1 to day 14/15. No major antitumor responses were observed. However, one patient with non-small-cell lung cancer and one with cutaneous squamous cell carcinoma had stable disease for 33 and 24 weeks, respectively. Conclusion: The MTD of once-daily oral EKB-569 is 75 mg. The tolerable toxicity profile and long half-life of this irreversible EGFR inhibitor warrant its further evaluation as a single agent and in combination with other drugs.

UR - http://www.scopus.com/inward/record.url?scp=33744824672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744824672&partnerID=8YFLogxK

U2 - 10.1200/JCO.2005.01.8960

DO - 10.1200/JCO.2005.01.8960

M3 - Article

C2 - 16710023

AN - SCOPUS:33744824672

VL - 24

SP - 2252

EP - 2260

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 15

ER -